Camurus Second Quarter 2024 Earnings: EPS Misses Expectations

Camurus (STO:CAMX) Second Quarter 2024 Results

Key Financial Results

• Revenue: kr444.9m (down 34% from 2Q 2023).
• Net income: kr74.2m (down 75% from 2Q 2023).
• Profit margin: 17% (down from 45% in 2Q 2023).
• EPS: kr1.28 (down from kr5.44 in 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Camurus EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 11%.

Looking ahead, revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 38% growth forecast for the Pharmaceuticals industry in Sweden.

Performance of the Swedish Pharmaceuticals industry.

The company's shares are up 5.5% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Camurus, and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com